CWM
AXSM icon

Cabot Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Cabot Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$940K Hold
5,560
– – 0.11% 94
2025
Q4 		$1.02M Hold
5,560
– – 0.11% 95
2025
Q3 		$675K Buy
+5,560
New +$626K 0.07% 102

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cabot Wealth Management's AXSM Position: Q1 2026 in Review

Cabot Wealth Management held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 5,560 shares worth $940K. The position accounts for 0.11% of the portfolio, ranked #94.

Cabot Wealth Management first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.02M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Cabot Wealth Management held 5,560 shares of Axsome Therapeutics worth $940K as of Q1 2026.
  • Cabot Wealth Management left its Axsome Therapeutics share count unchanged in Q1 2026.
  • Axsome Therapeutics made up 0.11% of Cabot Wealth Management's portfolio in Q1 2026, its #94 holding.
  • Cabot Wealth Management first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Cabot Wealth Management's Axsome Therapeutics position peaked at $1.02M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Cabot Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.